K.W. Lee, Journalist Who Gave a Voice to Asian American Communities, Dies at 96

Fortitude Gold (OTC:FTCO) reported Q2 2025 earnings on August 5, revealing GAAP revenue of $4.9 million and earnings per share of $0.04, a 49% decline in sales from Q2 2024 due to lower production at the Isabella Pearl mine. Despite operational challenges, the company achieved a net income of $0.8 million, focusing on cost management and regulatory compliance while preparing for its next project, County Line. Want More Context? 🔎

Halozyme Therapeutics (NASDAQ:HALO) reported strong Q2 2025 results on August 5, with EPS of $1.54, exceeding the $1.24 consensus and marking a 69.2% year-over-year increase. Revenue reached $325.7 million, surpassing expectations by 13.9% and reflecting a 41% annual growth, prompting the company to raise its FY2025 guidance amid robust royalty growth and expanding technology partnerships. Want More Context? 🔎

Caterpillar (NYSE:CAT) reported Q2 FY2025 results on August 5, 2025, with GAAP revenue of $16.57 billion, exceeding expectations, but Adjusted profit per share at $4.72 fell short of the $4.89 forecast. Despite a 1% year-over-year revenue decline due to cost pressures, material margin declines, and new tariffs, the company continues to serve diverse industries globally with its extensive range of heavy machinery and financial products. Want More Context? 🔎

Hillman Solutions (NASDAQ:HLMN) reported Q2 FY2025 GAAP revenue of $402.8 million, exceeding estimates of $389.8 million, with adjusted EPS of $0.17 surpassing the $0.14 forecast. Despite a 6.2% increase in net sales and strong customer relationships, the company faces challenges with free cash flow and customer concentration, primarily relying on major retailers like Home Depot and Lowe’s. Want More Context? 🔎

Things are worsening for UnitedHealth Group (NYSE: UNH), with a significant drop in stock value—losing half its worth in 2025—amid poor financial results, a CEO change, and a Department of Justice investigation. Following a disappointing earnings report, the stock's future remains uncertain, prompting questions about whether it is best to avoid or consider as a contrarian investment. Want More Context? 🔎

DuPont de Nemours (NYSE:DD) reported Q2 2025 earnings on August 5, achieving adjusted EPS of $1.12, exceeding expectations, and GAAP revenue of $3,257 million, slightly above consensus. The company experienced significant growth in its electronics and healthcare segments, prompting management to raise full-year guidance despite a GAAP goodwill impairment in its Aramids business. Want More Context? 🔎